Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 10,173 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 10,173 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the transaction, the chief executive officer owned 392,483 shares of the company’s stock, valued at approximately $2,504,041.54. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO traded up $0.02 during trading hours on Friday, hitting $6.29. The stock had a trading volume of 659,585 shares, compared to its average volume of 740,432. The business’s 50 day moving average is $8.30 and its 200-day moving average is $7.63. The company has a market cap of $459.11 million, a price-to-earnings ratio of -2.33 and a beta of 1.78. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $10.99.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LXEO. Raymond James Financial started coverage on Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. Chardan Capital reissued a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. Cantor Fitzgerald began coverage on shares of Lexeo Therapeutics in a research note on Monday, December 1st. They issued an “overweight” rating and a $19.00 price target on the stock. Finally, HC Wainwright reduced their price target on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. Allworth Financial LP lifted its position in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after buying an additional 1,459 shares during the last quarter. California State Teachers Retirement System lifted its position in Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after buying an additional 2,148 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Lexeo Therapeutics by 160.2% during the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock worth $58,000 after buying an additional 3,615 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Lexeo Therapeutics by 42.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after buying an additional 2,799 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.